Open AccessProtein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives
Author(s) -
Charles J. Malemud,
David E. Blumenthal
Publication year - 2014
Publication title -
world journal of orthopedics
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.76
H-Index - 43
ISSN - 2218-5836
DOI - 10.5312/wjo.v5.i4.496
Subject(s) - tofacitinib , janus kinase , medicine , rheumatoid arthritis , tyrosine kinase , signal transduction , protein kinase a , kinase , small molecule , protein kinase b , jak stat signaling pathway , cancer research , arthritis , pharmacology , pi3k/akt/mtor pathway , immunology , microbiology and biotechnology , biology , receptor , biochemistry , cytokine
Medicinal chemistry strategies have contributed to the development, experimental study of and clinical trials assessment of the first type of protein kinase small molecule inhibitor to target the Janus kinase/Signal Transducers and Activators of Transcription (JAK/STAT) signaling pathway. The orally administered small molecule inhibitor, tofacitinib, is the first drug to target the JAK/STAT pathway for entry into the armamentarium of the medical therapy of rheumatoid arthritis. The introduction of tofacitinib into general rheumatologic practice coupled with increasing understanding that additional cellular signal transduction pathways including the mitogen-activated protein kinase and phosphatidylinositide-3-kinase/Akt/mammalian target of rapamycin pathways as well as spleen tyrosine kinase also contribute to immune-mediated inflammatory in rheumatoid arthritis makes it likely that further development of orally administered protein kinase small molecule inhibitors for rheumatoid arthritis will occur in the near future.